Key result
Cangrelor shows potential as the preferred ACS antiplatelet but needs direct comparisons with oral P2Y12 inhibitors.
Why the study?
Does cangrelor offer a more favorable pharmacokinetic and pharmacodynamic profile compared to oral P2Y12 inhibitors in patients with acute coronary syndrome or undergoing elective percutaneous coronary intervention?
Does cangrelor offer a more favorable pharmacokinetic and pharmacodynamic profile compared to oral P2Y12 inhibitors in patients with acute coronary syndrome or undergoing elective percutaneous coronary intervention?
Cangrelor's immediate onset and quick offset of action make it a promising agent for acute coronary syndrome and elective PCI, but further comparative studies against newer oral P2Y12 inhibitors are required.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Should not yet change ACS antiplatelet practice; leaves open cangrelor's superiority over prasugrel or ticagrelor.
Clopidogrel has been widely investigated, even if resistance limits its efficacy. Prasugrel and ticagrelor obtain a greater and homogeneous inhibition of platelet aggregation, but a delay onset of action in patients with stent thrombosis elevation myocardial infarction and an increased bleeding risk in case of surgical revascularization have been reported. Cangrelor is an intravenous reversible P2Y12 inhibitor with an immediate onset and a quick offset of action. Based on its pharmacokinetic and pharmacodynamic profile, and on clinical data, cangrelor could become the antiplatelet of choice in case of elective percutaneous coronary intervention without clopidogrel pretreatment and in acute coronary syndrome requiring urgent coronary angiography. However, in acute setting, data of comparison with prasugrel and ticagrelor are needed.
Ferlini et al. (2014) conducted a review in Acute coronary syndrome. Cangrelor vs. Prasugrel and ticagrelor was evaluated. Cangrelor, an intravenous reversible P2Y12 inhibitor, shows potential as the antiplatelet of choice for acute coronary syndrome, though direct comparisons with prasugrel and ticagrelor are needed.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: